



# UV-A MEDICAL DEVICE FOR THERANOSTIC GUIDED CORNEAL CROSS-LINKING

## TRANSFORMATIVE TECHNOLOGY

Scientifically and clinically validated Theranostics technology

### EXPONENTIAL & KEY-ENABLING TECHNOLOGIES

- **Augmented reality** for precise corneal focusing ( $\pm 0.2$  mm) with integrated Placido disc technology
- **Internet Of Medical Things** for remote control and predictive maintenance (USB tethering or LAN connection)
- **Artificial intelligence** for the continuous improvement of device performance
- **Digital traceability** for clinical data storing and export

### PRE-SET PROTOCOLS AND UNLIMITED ADD-ON OPTIONS

- UV-A energy dose:  $3.6 \text{ J/cm}^2$  to  $10.0 \text{ J/cm}^2$
- UV-A power density:  $3 \text{ mW/cm}^2$  to  $40 \text{ mW/cm}^2$
- UV-A irradiation mode: continuous or pulsed
- UV-A beam size from 5 mm to 9 mm diameter
- "Enhanced epi-on" algorithm

**MAXIMUM RELIABILITY** double monitoring system of UV-A power density (accuracy  $\pm 0.1 \text{ mW/cm}^2$ )

**SUSTAINABLE TECHNOLOGY** with optimized energy consumption

**GRAPHIC USER INTERFACE** on 10.1" full HD touch screen with colour display

**INTEGRATED INTERCONNECTION WITH PROPRIETARY CORNEAL IONTOPHORESIS**

**EASY HANDLING** • Articulated and balanced arm (positioning accuracy: 0.2 mm)  
• Wheeled cart


**INDICATION OF USE** Treatment of pathological conditions of the cornea with theranostic-guided corneal cross-linking procedures

**EU MDR CERTIFICATION CE1936:** class IIb active medical device

**IP PROTECTION** Patent Family ITUB20160237, EP3407920, US11612518 and CN108697814



TECHNICAL DATASHEET



**THERANOSTIC PLATFORM** halts keratoconus progression and improves visual acuity with predictive personalization of the clinical outcome

# RITSIGHT

## 0.22% RIBOFLAVIN OPHTHALMIC SOLUTION FOR CORNEAL CROSS-LINKING

### UNIQUENESS THAT MEET THE SURGEONS' NEEDS

- 0.30% Riboflavin 5-phosphate (equivalent to 0.22% riboflavin base)
- Maximum stability of riboflavin for 36 months
- Hypotonic solution, viscoelastic-free
- 3.0 ml volume
- Storage at room temperature (4°C - 25°C)
- UDI with digital traceability (Data Matrix Code)

### VERSATILE

Exclusive solution for all CXL protocols (epi-off, epi-on)

Indicated for thin corneas (minimum thickness 370 µm)

Indicated for manual application or with controlled corneal iontophoresis

### INDICATION OF USE

Protection of the inner structures of the eye during corneal cross-linking procedures for treatment of ectatic corneal diseases, bullous keratopathy and infectious keratitis.

*The only riboflavin validated for theranostic-guided corneal cross-linking*

**EU MDR CERTIFICATION CE0477:** Class IIb sterile medical device

**IP PROTECTION** Patent Family IT201900011985, US20230131004 and CN114126650



# DoRSight

## CORNEAL IONTOPHORESIS CONTROLLED DELIVERY SYSTEM For exclusive use with C4V CHROMO4VIS

### INDICATION OF USE

Transepithelial application of riboflavin in the cornea prior to UV-A light irradiation with C4V CHROMO4VIS in theranostic-guided corneal cross-linking procedures.

### UNIQUENESS

The integration of DoRSight with C4V CHROMO4VIS technology enables a sophisticated approach for **fast** and **precise patterned delivery** of riboflavin in the cornea, allowing, through theranostic-guided UV-A light photo-therapy, for:

- Enhancing precisely the regional tissue biomechanics
- Improving significantly the optical quality of the cornea

### EU MDR CERTIFICATION CE1936:

Class IIa sterile accessory medical device

**IP PROTECTION** Patent Family IT102019000010341, EP3989895, US20220233842 and CN114025835



discover more at  
[www.regensight.com](http://www.regensight.com)

RSMKTKC21009EN

*This information material is intended for healthcare professionals only.*